Chi-Chung Li 1 , Steve Vermeersch , William S Denney , William P Kennedy , John Palcza , Adrianna Gipson , Tae H Han , Rebecca Blanchard , Inge De Lepeleire , Marleen Depré , M Gail Murphy , Kristien Van Dyck , Jan N de Hoon
Calcitonin gene related peptide (CGRP) receptor antagonists are effective acute migraine treatments. A capsaicin-induced dermal vasodilatation (CIDV) model has been developed to provide target-engagement information in healthy volunteers. In the model, CGRP release is provoked after dermal capsaicin application, by activating transient receptor potential vanilloid-type-1 (TRPV1) receptors at peripheral sensory nerves. Laser Doppler imaging is used to quantify CIDV and subsequent inhibition by CGRP receptor antagonists. We sought to evaluate a CGRP receptor antagonist, MK-3207, in the biomarker model and to assess the predictability of the CIDV response to migraine clinical efficacy.